Pioneering the Future of Nephrotic Syndrome Research with ARREST-NEPHROSIS
Nephrotic Syndrome affects millions globally, presenting a significant health burden with its hallmark symptoms of severe proteinuria and edema. The ...
Read More
Delta4 At BIO-Europe
Delta4 at BIO-Europe 2023: Fostering Partnerships and Driving Innovation We are excited to share Delta4’s presence at the recently concluded ...
Read More
Digital Health Envision Summit
We are delighted to announce that Dr. Klaus Kratochwill, CSO, and Dr. Paul Perco, Computational Biology Lead of Delta4, are ...
Read More
Case Study: Unravelling the Multifaceted Potential of Iguratimod with Delta4’s Hyper-C Platform
Diving deep into the realms of computational drug repurposing, Delta4 leveraged its state-of-the-art Hyper-C platform with an ambitious objective: to ...
Read More
Delta4 at RExPO: Pushing the Boundaries of Drug Repurposing
We are thrilled to announce that Delta4 will be in attendance at this year’s RExPO23, a landmark event in the ...
Read More
Reactome Spotlights Delta4’s Computational Drug Repositioning of Clopidogrel for FSGS
We are honored to announce that our publication on the computational drug repositioning of clopidogrel has been highlighted in the ...
Read More
Delta4 joins the EU-funded COST action PerMediK (Personalized medicine in chronic kidney disease: improved outcome based on Big Data)
The scientific goal of PerMediK is to foster development toward personalized medicine in chronic kidney disease (CKD), based on multidimensional ...
Read More
Delta4’s Innovation Shines: OntoloViz Article Published in Bioinformatics Advances Journal
We are thrilled to announce that our journal article, titled “OntoloViz: a GUI for interactive visualization of ranked disease or ...
Read More
Delta4 Identifies a Potential New Therapeutic Option for Focal Segmental Glomerulosclerosis (FSGS) using computational Hyper-C Drug Discovery Platform
Delta4, a digital drug discovery company, identified a potential therapeutic option for Focal Segmental Glomerulosclerosis (FSGS) using their Hyper-C AI ...
Read More
Delta4 CEO Kurt Herpel Featured in Insightscare Magazine: A Vision for the Future of Drug Discovery
We are incredibly proud to share that our esteemed CEO, Kurt Herpel, has recently been profiled in Insightscare Magazine. In ...
Read More
Delta4 Announces Prof. Doron Lancet To Join Scientific Advisory Board
VIENNA, Austria, March 6th, 2023 — Delta4, a digital drug discovery company focusing on the identification of new indications for ...
Read More
4P-Pharma And Delta4 Join Forces To Find And Develop Treatments For A Rare Autoimmune Chronic Liver Disease
Paris (France) and Vienna (Austria), 31st May 2022 – 4P-Pharma, a French clinical-stage biotechnology company, and Delta4, an Austrian digital ...
Read More
Delta4, in preparation for the first clinical study, focused on FSGS
Focal Segmental Glomerulosclerosis (FSGS) is a devastating clinical condition with defined glomerular histopathology and yet a multifaceted pathophysiological, histological, and ...
Read More
Delta4 at BIO-EUROPE 2021
From October 25-28 Delta4 attended the (virtual) BIO-EUROPE conference, the largest partnering event in Europe dedicated to the global biotechnology ...
Read More
Delta4 Announces Dr. Hans Lehrach to Join Scientific Advisory Board
VIENNA, Austria, September 27th, 2021 — Delta4, a digital drug discovery company focusing on the identification of new indications for ...
Read More
Delta4 expands Team and tackles new indications
A Welcome to Our Newest Member Following our Financing in March 2021 and our move into new premises in July ...
Read More
Office News – July ’21
We are excited to announce that Delta4 has moved into a new office in the 8th district, close to the city ...
Read More
Alfred Steininger to Join Delta4 as CFO
We are very pleased to introduce Alfred Steininger as our new Chief Financial Officer, starting in mid-July 2021. Alfred brings ...
Read More
Press Release – April ’21
Delta4 Announces Closing of Multi-million Series A Financing Round Company to Expand Focus Beyond Renal Diseases and COVID-19 Compounds Identified ...
Read More
FSGS and COVID-19 programs ready for Phase II studies
We are proud to announce further progress in our current drug discovery and development programs. In late 2020, Delta4 filed ...
Read More
Delta4 files four patent applications in FSGS and COVID-19
We are very pleased to announce that Delta4 has filed four patent applications for compounds and combinations of compounds in ...
Read More
BIO-Europe 2020 Digital – Partnering Event
Global connections are more important than ever. With the same powerful one-to-one partnering and valuable content, BIO-Europe Digital continues to ...
Read More
Sachs 20th Annual Biotech In Europe Forum
The 20th Annual Biotech in Europe (BEF) Forum is recognized as the leading international Stage for those interested in investing ...
Read More
World Orphan Drug Congress
With over 1,500 attendees from 50+ countries, the 2020 edition of the World Orphan Drug Congress USA was held online ...
Read More
Press Release – June 2020
Delta4 Announces Results Achieved with Drug Discovery Platform Vienna, Europe (June 2, 2020) – Delta4, a biotech company using its ...
Read More
COVID-19 – Call to Action
The global crisis caused by the SARS-Cov2 outbreak requires rapidly applicable therapeutics. Available approved drug substances represent one of the ...
Read More
Biotech Showcase 2020 @JPM San Francisco
What Is It? Biotech Showcase™ is an investor conference during JPM 2020, devoted to providing private and public biotech companies ...
Read More
LSX Investival
Delta4 Reflects on the 2020 LSX Investival Showcase: A Landmark Event in Life Sciences Innovation In November 2020, the prestigious ...
Read More
Life-Science Investment Days, Vienna
Delta4 Attends the Life Science Investment Days Event of 2019 The Life Science Investment Days event held in Vienna from ...
Read More
Biotech in Europe Forum (BEF)
Delta4’s Participation at the 19th Annual Biotech in Europe Forum: A Landmark Experience Delta4 was honored to attend the 19th ...
Read More
Stay Up-to-Date with Our Insider Newsletter
Stay up to date with news, important events, the trends we’re watching, and what we’re working on.
